Nico Gagelmann
Jun 18, 2025, 15:13
李宁公司2017财报发布：年收入增长11%，毛利上升13%
百度 汪洋指出，长期以来，各民主党派始终同中国共产党肝胆相照、荣辱与共，为我国革命、建设和改革事业作出了重要贡献。
Nico Gagelmann, Young National Society Ambassador at European Hematology Association (EHA) and Chair of the CAR-T for plasma cell disorder committee at The EBMT, shared a post on X:
“Out now in Journal of Clinical Oncology.
Closing the Gap: PTCy Boosts Survival After Mismatched Stem Cell Transplants
Summary:
In a multicenter phase II trial, post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis enabled strong 1-year survival outcomes in patients receiving peripheral blood stem cell transplants from HLA-mismatched unrelated donors (MMUDs).
Among 145 patients – 59% from underrepresented groups – 1-year overall survival reached 83.8% (MAC) and 78.6% (RIC/NMA), with low rates of severe GVHD.
Outcomes were comparable regardless of the degree of mismatch. These findings suggest PTCy regimens can safely expand donor access across all ethnic backgrounds.”
More posts featuring Nico Gagelmann on OncoDaily.
Abeer Madbouly
Alison Loren
Antonio Martin Jimenez Jimenez
ASCO
Brent Logan
Brian C. Shaffer
Bronwen E. Shaw
cancer
Craig Malmberg
Dipenkumar Modi
EHA
Erin Leckrone
European Hematology Association
Farhad Khimani
Heather E. Stefanski
Janelle Olson
Jeffery J. Auletta
Jianqun Kou
Journal of Clinical Oncology
Juan Wu
Karen Ballen
Karilyn Larkin
Larisa Broglie
Mahasweta Gooptu
Martin Maiers
Medhat Askar
Mehdi Hamadani
Monzr M. Al Malki
Muna Qayed
Nico Gagelmann
OncoDaily
Oncology
post-transplant cyclophosphamide
PTCy
Rachel Cook
Rachel Cusatis
Sally Arai
Sarah Smith
Stem Cell Transplants
Stephanie Bo-Subait
Stephanie Fingerson
Stephen R. Spellman
Steven Michael Devine
Sung Won Choi
The EBMT
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 5, 2025, 19:11
Aug 5, 2025, 18:55
Aug 5, 2025, 18:30
Aug 5, 2025, 18:18